Healthcare Industry News:  lumbar spinal stenosis 

Devices Orthopaedic Neurosurgery FDA

 News Release - July 1, 2009

Applied Spine Technologies to Restart U.S. Clinical Trial for Stabilimax NZ(R) Dynamic Spine Stabilization System

NEW HAVEN, Conn.--(HSMN NewsFeed)--Applied Spine Technologies (AST), Inc. (, a medical device company focused on motion preservation of the lumbar spine, announces that it has received permission from the U.S. Food and Drug Administration (FDA) to proceed with enrollment in their IDE trial of the Stabilimax NZ(R) Dynamic Spine Stabilization System.

The trial resumes after AST voluntarily suspended enrollment in August 2008 following three reports of screw fracture. After collaborating with Exponent, Inc., an engineering and scientific consulting firm, changes to the surface finishing technique were recommended and implemented. The result was a significant increase in the longevity under fatigue loading of the screw according to testing data.

Recently appointed President and CEO Craig Corrance said, “Voluntary suspension of enrollment late last year was the correct decision to make and management showed terrific fortitude in making that decision. AST is now eager to resume patient enrollment and we look forward to building upon the impressive results we have obtained so far.”

Clinical Investigator Neel Anand, M.D. agrees, stating “I am most pleased to commence with re-enrollment. The Stabilimax NZ system has the potential to address an important sector within the degenerative lumbar spine segment. Preserving motion while reducing pain, and offsetting the risk of future adjacent level symptoms, is an attractive proposition for both patient and physician.”

About the IDE Clinical Trial

Applied Spine Technologies, Inc. has received permission from the FDA to resume a multi-center, randomized, controlled clinical trial to compare posterior dynamic stabilization using the Stabilimax NZ(R) Dynamic Spine Stabilization System to traditional spinal fusion stabilization to treat degenerative lumbar spinal stenosis. AST has enrolled over 100 patients to date.

About Applied Spine Technologies Inc., and Stabilimax NZ(R)

Applied Spine Technologies Inc., headquartered in New Haven, Connecticut, is developing Stabilimax NZ, a posterior dynamic stabilization device designed to support an injured or degenerated spine without eliminating motion. Stabilimax NZ is expected to offer numerous advantages over current spinal fixation products and even new artificial disc products—including a much less invasive and less traumatic implant procedure, maintenance of spine motion and disc function, and the potential to prevent or slow adjacent-segment disc disease.

Source: Applied Spine Technologies

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.